Last updated on July 2017

A Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)


Brief description of study

A Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

Detailed Study Description

The purpose of this research study is to see if nivolumab and ipilimumab in combination with chemotherapy is better at improving survival when compared to standard chemotherapy treatment. This study will also test the effectiveness (how well the drug works), safety, and tolerability of the nivolumab and ipilimumab combined with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).

Clinical Study Identifier: TX151355

Contact Investigators or Research Sites near you

Start Over

Nurdan

Baptist Health Clinical Research Center & Lexington Cardiac Research Foundation
Lexington, KY USA
  Connect »